Clinical trials
2 active studies led by CorMedix Therapeutics, of 6 in all
Source: ClinicalTrials.gov, Studies with CorMedix Therapeutics (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
- 0Reports naming them
- 1Markets in public records
- 0Regions & countries
- 2Active trials they lead[1]
[1] ClinicalTrials.gov, Studies led by CorMedix Therapeutics or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
Free public data on CorMedix Therapeutics
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
See them on ClinicalTrials.gov (opens in a new tab)
US drug approvals
1 approvals with a product on the US market
- Defencath NDA214520 · approved 15 Nov 2023
Source: Drugs@FDA, Approvals (NDA, ANDA, BLA) held, with a product sold now; newest shown. Retrieved 13 Nov 2026.
Trials over time
Studies CorMedix Therapeutics leads, by the year they started and their phase
- Phase 1
- Phase 2
- Phase 3
- Phase 4
- No phase (devices, observational)
Source: ClinicalTrials.gov, Studies with CorMedix Therapeutics or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.
Markets where public records show them
Markets we cover where free public records show CorMedix Therapeutics: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
Topics
The topics of the markets CorMedix Therapeutics is in.
From our blog
Stories on the topics CorMedix Therapeutics works in.
Dermatology Diagnostics: AI and Skin Health
Skin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions…
Read
Ambulance Services: The First Link in Emergency Care
More than half of deaths in low- and middle-income countries come from conditions emergency care could treat…
Read
Molecular Point-of-Care Tests: Lab Accuracy, Clinic Speed
TB killed 1.23 million people in 2024. WHO now recommends rapid molecular tests first, bringing lab-grade…
Read